Heidelberg Pharma AG, a clinical
stage company developing innovative Antibody Drug Conjugates (ADCs), will present new
data from its Phase I/IIa clinical study with lead Amanitin-based ADC candidate, pamlectabart
tismanitin (HDP-101), at the 23rd International Myeloma Society (IMS) Annual Meeting, being
held in Glasgow, Scotland, on 23 to 26 September 2026.
• Existing partnership will be broadened through joint research and development of new Antibody Drug Conjugates (ADCs) involving up to six targets
• Heidelberg Pharma’s pipeline will be expanded with new product candidates
• Both parties to contribute their strength and proprietary technologies, including Heidelberg Pharma’s ADC technology
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the China National Medical Products Administration (NMPA) has granted Clinical Trial Approval for a Phase Ib/II clinical trial evaluating pamlectabart tismanitin (HDP-101), the Company’s novel BCMA-targeting ADC, in combination therapy for the treatment of patients with relapsed/refractory multiple myeloma.
Immatics N.V. (“Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced today that it has agreed to sell 12,945,916 ordinary shares at $8.69 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 4,315,304 ordinary shares at a purchase price of $8.689 per pre-funded warrant, which represents the per share offering price less the $0.001 per share exercise price for each pre-funded warrant, in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $150 million. The offering is expected to close on August 26, 2026, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,589,184 additional shares at the public offering price, less the underwriting discount.
• ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome
• Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration
• Based on PK data the therapeutic dose is expected to be ≤10mg once daily
• To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a cardiovascular risk cohort is now underway with initial results expected by year end
• Full results from the Phase 1/1b trial are expected in H1 2027
• Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203)
remains on track to complete the required randomizations by year-end to support final
analysis for the primary PFS endpoint; aggregate PFS events (progression or death)
occurring more slowly than originally modeled
Cosmo N.V. today announced that it will change its ticker symbol on the SIX Swiss Stock Exchange from “COPN” to “CMHC”. This change is expected to take effect at the opening of trading on Monday, August 17, 2026.
• Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance
• Recent positive interim results showed safety and immunogenicity with early signals of activity
• Full week-100 results from Part 1 of VacSYn trial expected in H2 2026
Cosmo N.V. (“Cosmo”), a global leader in AI-driven healthcare and specialty pharmaceuticals, today reported financial results for the first half of 2026. During the period, the Company delivered double-digit growth in recurring revenues, advanced its dermatology pipeline toward regulatory submission, further strengthened the GI Genius™ platform with next-generation commercial and technological capabilities, and maintained a strong financial position. Cosmo ended the reporting period debt-free, with more than €205 million in cash, cash equivalents and investments, and reaffirms its full-year 2026 financial guidance.
Immatics N.V. (“Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced three presentations at the European Society for Medical Oncology (ESMO) Congress 2026, to be held from October 23-27, 2026, in Madrid, Spain.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today published its financial report on the first six months of 2026 (1 December 2025 – 31 May 2026) and reported on the course of business.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces three presentations at the Alzheimer’s Association International Conference® 2026, taking place July 12-15 in London, UK.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim data from the first three cohorts (AD1, AD2 & AD3) of 74 patients with prodromal Alzheimer’s disease (AD) in the Phase 1b/2 ABATE trial following 12 months of treatment with ACI-24 anti-amyloid beta (Abeta) active immunotherapy.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the company’s shareholders approved the management proposals with a large majority (between 98.67% and 98.72%) at today’s ordinary virtual Annual General Meeting.
Cosmo N.V. (“Cosmo”) is pleased to announce the launch of its innovative acne cream Winlevi® (clascoterone 1% cream) in Austria and Germany by its commercial partner InfectoPharm Arzneimittel und Consilium GmbH (“InfectoPharm”). Winlevi® is available in both countries since June 1. Cosmo is the exclusive manufacturer of the product.
Cosmo N.V. (“Cosmo”) is pleased to make known that its commercial partner Glenmark Specialty S.A (GSSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd., today announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in adolescents limited to facial application) by the European Commission to Cassiopea S.p.A., a subsidiary of Cosmo N.V., in October 2025.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will receive a research grant of $4 million from The Vijay and Marie Goradia Charitable Foundation. The grant will support extending Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, AC Immune’s anti-alpha-synuclein (a-syn) active immunotherapy, in early Parkinson’s disease (PD).
Immatics N.V. (“Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced extended data from the ongoing Phase 1b clinical trial evaluating anzu-cel (anzutresgene autoleucel, IMA203) PRAME TCR T-cell therapy in heavily pretreated patients with advanced melanoma in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, USA. The dataset is focused on patients treated with anzu-cel at the recommended Phase 2 dose (RP2D), including longer follow-up and further characterization of the durability and systemic nature of the observed clinical responses.
Immatics N.V. (“Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced the presentation of extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific (TCER®) candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients with solid tumors, including head and neck cancer and lung cancer, in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. The data show a consistent and favorable tolerability profile across multiple tumor types and encouraging anti-tumor activity at the recommended Phase 2 dose (RP2D) with or without the immune checkpoint inhibitor (ICI) pembrolizumab. Results from the Phase 1 study are being published simultaneously in Nature Medicine.
Immatics N.V. (“Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. One-time infusion of IMA203CD8 demonstrated meaningful clinical activity across different tumor types as well as manageable tolerability. The broad expression of PRAME in more than 50 cancers further supports the continued development of IMA203CD8 in multiple PRAME-positive solid tumors.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the presentation of new preliminary data from a Phase 1 trial of its first-in-class TDP-43 positron emission tomography (PET) tracer ACI-19626 showing increased uptake in the brains of patients with amyotrophic lateral sclerosis (ALS).
Cosmo N.V. (“Cosmo” or “the Company”) today announced the completion of patient enrolment in its Phase II clinical trial (EUCT number: 2023-506917-23-00) evaluating its novel investigational therapy, Rifamycin enema, for the treatment of distal ulcerative colitis (UC) and ulcerative proctitis. A total of 77 patients were enrolled at 24 clinical sites in Europe, reflecting strong investigator engagement and efficient study execution.
Immatics N.V. (“Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today provided a business update and reported financial results for the quarter ended March 31, 2026.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces that Dr Andrea Pfeifer has decided to retire from her role as Chief Executive Officer (CEO) of AC Immune at the upcoming Annual General Meeting (AGM) to spend more time with her family.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today provided financial and corporate updates for the quarter ended March 31, 2026.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it dosed the first patients in Cohort AD4 in the ongoing Phase 1b/2 ABATE trial. As a result, AC Immune will receive a $12 million milestone payment from Takeda under the partners’ exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24 for the treatment of Alzheimer’s disease (AD).
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today reported on the first three months of fiscal year 2026 (1 December 2025 – 28 February 2026) and the Group’s financial figures.
Immatics N.V. (“Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced all submitted abstracts have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29-June 2, 2026, in Chicago, Illinois, USA.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), announces the change of its Chief Financial Officer. The current Chief Financial Officer of Heidelberg Pharma AG, Mr. Walter Miller, is leaving Heidelberg Pharma AG at his own request upon the expiration of his employment contract to pursue new professional challenges. Mr. Peter Willinger will assume the role of Chief Financial Officer effective 1 May 2026.
Immatics N.V. (“Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced that an abstract highlighting a pediatric patient treated with a PRAME-directed cell therapy using Immatics’ PRAME T-cell receptor (TCR) has been accepted for a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California, USA. The patient case will be presented on April 21, 2026, at 2:00 pm PDT (Late-Breaking Research: Clinical Research 3; Poster Section 52; Poster Board Number 7; Abstract Number LB326) by the treating physician, Dr. med. Christian M. Seitz, Group Leader at the Hopp Children’s Cancer Center Heidelberg (KiTZ).
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced positive 12-month Phase III results for Clascoterone 5% topical solution in men with mild-to-moderate androgenetic alopecia (AGA), reinforcing the product’s potential to redefine treatment in one of the largest and most underserved categories in dermatology. The data confirm three critical attributes physicians and patients have been waiting for: long-term safety, continued efficacy with ongoing use, and a novel mechanism designed to target the underlying biology of hair loss.
Cosmo Pharmaceuticals N.V. announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting (AGM). A total of 10,354,065 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 59.02% of the total outstanding ordinary shares in the share capital of Cosmo as of the record date.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the determination of the recommended Phase II dose (RP2D) in its Phase I/IIa study with pamlectabart tismanitin (HDP-101) for the treatment of relapsed or refractory multiple myeloma. Heidelberg Pharma’s Benefit and Risk Assessment team agreed with the recommendation by the study’s Safety Review Committee (SRC), which had conducted a comprehensive review of safety, tolerability and pharmacokinetic (PK) data from the Company’s ongoing Phase I/IIa trial.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced an agreement with Eli Lilly and Company (Lilly) to amend their 2018 license and collaboration agreement to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases. The amendment continues the research and collaboration to cover development of new lead Tau Morphomer® candidates and potential back-up compounds.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), will present promising preclinical data from its Amanitin-based ADC HDP-103 targeting metastatic castration-resistant prostate cancer (mCRPC) at the American Association of Cancer Research (AACR) Annual Meeting 2026 in San Diego, California, USA, from 17 to 22 April.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today published its financial results and Annual Report for fiscal year 2025 (1 December 2024 – 30 November 2025) and its outlook for 2026.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the presentation of Phase 1 data including the first in vivo images of TDP-43 pathology in the human brain, detected using its first-in-class positron emission tomography (PET) tracer ACI-19626, at the International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2026).
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its partner Huadong Medicine Co., Ltd., Hangzhou, China, (SZ 000963; Huadong) has reached a development milestone under the terms of the license agreement from February 2022. With the dosing of the first patient in a clinical study with HDP-101 (INN: pamlectabart tismanitin) in China, a planned milestone payment to Heidelberg Pharma became due and is being processed. Financial details were not disclosed.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced its participation at NVIDIA GTC 2026, the world’s leading conference for artificial intelligence (AI) and accelerated computing, taking place in San Jose (CA), USA, from March 16 to March 19.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, 2025, and provided a corporate update.
Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce the convening of its upcoming Ordinary Annual General Meeting of Shareholders (AGM) to be held on 10 April 2026 in Amsterdam.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), announced on 7 March an additional amendment to its existing royalty purchase agreement with HealthCare Royalty (HCRx) and the participation of Soleus Capital Management, L.P. (Soleus Capital), a US-based life sciences investment firm, on behalf of its Soleus Capital Credit Opportunities Fund I, L.P. (and its affiliated funds). The amended agreement covers the partial monetization of Heidelberg Pharma’s future royalties on the worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent TLX250-Px. In conjunction with the amendment, Heidelberg Pharma is eligible to receive USD 20 million from Soleus Capital, subject to customary closing conditions. Another payment of USD 25 million will become due upon FDA approval of TLX250-Px.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today reports its audited financial results for the fiscal year ended December 31, 2025. The Company also publishes its 2025 Annual Report and ESG Report 2025, available on its corporate website under www.cosmohealthconfidence.com/key-financial-reports.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced an additional amendment to its existing royalty purchase agreement with HealthCare Royalty (HCRx) and the participation of Soleus Capital Management, L.P. (Soleus Capital), a US-based life sciences investment firm, on behalf of its Soleus Capital Credit Opportunities Fund I, L.P. (and its affiliated funds). The amended agreement covers the partial monetization of Heidelberg Pharma’s future royalties on the worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent TLX250-Px. In conjunction with the amendment, Heidelberg Pharma is eligible to receive USD 20 million from Soleus Capital, subject to customary closing conditions. Another payment of USD 25 million will become due upon FDA approval of TLX250-Px.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today provided a business update and reported financial results for the quarter and full year ended December 31, 2025.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett’s esophagus. The collaboration represents an important step in expanding the clinical scope of Cosmo’s GI Genius™ platform beyond colorectal cancer screening into upper gastrointestinal (GI) indications.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will host an industry symposium on how a precision prevention approach to Parkinson’s disease may now be within reach, based on lessons from Alzheimer’s disease.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that the first participant has been dosed in a Phase 1 clinical trial of ACI-19764, an orally administered small molecule inhibitor of the NLRP3 inflammasome.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced the successful completion of a private placement of 937,086 treasury shares. The shares were placed with Capital Group’s SMALLCAP World Fund.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it has received a milestone payment under the terms of its license agreement with partner Takeda based on the achievement of a clinical development milestone for Takeda’s investigational medicine that utilizes Amanitin-based Antibody Drug Conjugate (ATAC) technology licensed from Heidelberg Pharma. With the dosing of the first patient in a Phase I/II clinical trial in patients with solid tumors, a milestone payment to Heidelberg Pharma became due. Financial details were not disclosed.
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases.
Cosmo Pharmaceuticals N.V. (“Cosmo”) reports strong preliminary unaudited 2025 revenue and year end cash, reflecting continued revenue growth and a robust cash position. Cosmo will publish its 2025 audited consolidated financial statements as well as the Annual and ESG Reports 2025 on March 9, 2026.
The past few months have been turbulent and difficult for Heidelberg Pharma. We have been confronted with events and changes that required swift and decisive action. Today, I am writing to you to explain where we stand – and, above all, why I am deeply convinced that the difficult path we have now embarked upon will be worthwhile.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced positive interim safety and efficacy results from the Phase 2 VacSYn trial of its wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in early Parkinson’s disease (PD).
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced updated Phase 1a dose escalation data from its second-generation PRAME cell therapy, IMA203CD8, in heavily pre-treated patients with solid tumors. Based on the enhanced pharmacology of IMA203CD8 reported previously, IMA203CD8 provides the potential to address difficult-to-treat solid tumors expressing PRAME beyond melanoma, such as ovarian cancer.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $125 million. The offering is expected to close on December 8, 2025, subject to customary closing conditions.
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced compelling topline results from its two pivotal Phase III trials of clascoterone 5% topical solution for male androgenetic alopecia (AGA, also known as male-pattern hair loss), marking a potential first major therapeutic breakthrough in hair-loss treatment in more than three decades.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the Supervisory Board has revoked the appointment of Professor Andreas Pahl as member of the Executive Management Board and Chief Executive Officer, and has instead appointed Dr Dongzhou Jeffery Liu as Chairman of the Executive Management Board and new Chief Executive Officer, with immediate effect.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today provided a business update and reported financial results for the quarter ended September 30, 2025.
Cosmo Pharmaceuticals N.V., a global leader in AI-driven healthcare and dermatology innovations, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgaris in patients aged twelve years and older. This milestone marks another key step in Cosmo’s mission to build health confidence worldwide, expanding access to its first-in-class topical anti-androgen to one of the largest dermatology markets in Latin America. With approval already granted in the Mexican market, availability of Winlevi® extends to over 50% of the Latin American population.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced updated Phase 1a dose escalation data from both product candidates in its TCR Bispecifics (TCER®) pipeline, IMA402 PRAME Bispecific and IMA401 MAGEA4/8 Bispecific, as well as next steps for clinical development.
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced two major milestones in its sustainability journey, underscoring its commitment to transparency, responsible operations, and ESG leadership.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that HDP-101 (INN: pamlectabart tismanitin), the Company’s lead ATAC candidate for the treatment of relapsed or refractory multiple myeloma, shows further clinical activity in Cohort 8 at a dose level of 140 µg/kg. These findings are highlighted by observed stringent complete remissions in two patients from Cohort 8.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended September 30, 2025, and provided a corporate update.
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced that it will participate in the following upcoming healthcare investor conferences:
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced that ColonPRO EU, the Company’s next-generation artificial intelligence software for colonoscopy, has received CE certification. Following FDA clearance in the United States, this certification brings to Europe the most advanced AI-assisted colonoscopy platform ever developed. The system has already been used to support more than four million procedures worldwide.
Heidelberg Pharma AG, a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announced the presentation of new clinical data from its ongoing Phase I/IIa clinical study evaluating its lead Amanitin-based ADC candidate, HDP-101 (INN: pamlectabart tismanitin), at the 16th Annual World ADC Congress, taking place in San Diego, California, from 3 to 6 November 2025.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the appointment of Prof. Catherine Mummery, a deeply experienced neurologist and expert in dementia clinical trials, as Chairwoman of its Clinical Advisory Board (CAB).
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer (“CPO”) effective October 27, 2025. Ms. Krause brings more than 20 years of experience in shaping culture, leading organizational growth and aligning talent with business strategy, including across global biopharmaceutical companies. In this newly established role, she will lead Immatics’ human resources, focusing on organizational development and operations as the company transitions to commercial stage.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the publication in Nature Communications of preclinical data on its first-in-class brain positron emission tomography (PET) tracers for imaging TDP-43 pathology. The selected candidate, ACI-19626, potentially enables a precision medicine approach to multiple neurodegenerative diseases that are currently difficult to diagnose and differentiate from each other.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that HDP-101 (INN: pamlectabart tismanitin), the Company’s lead Amanitin-based ADC candidate, has been granted Fast Track Designation by the US Food and Drug Administration (FDA).
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced that the European Commission has granted regulatory approval in the EU for Winlevi® (clascoterone 1% cream) for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years, with usage in adolescents limited to facial application. This formal approval came following on the positive recommendation for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on 25th of August 2025. Cosmo is already working at full speed with its commercial partners to prepare for launch across 20 European markets.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the presentation of updated data from 16 patients with metastatic uveal melanoma treated with anzu-cel PRAME cell therapy.
Heidelberg Pharma AG reported today on its operational progress as well as on the Group’s financial figures for the first nine months of fiscal year 2025 (1 December 2024 – 31 August 2025).
Cosmo Pharmaceuticals N.V., a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgaris in patients aged twelve years and older. This approval marks another important milestone in Cosmo’s global dermatology expansion and reinforces the Company’s commitment to delivering innovative, patient-centric therapies.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it has adjusted its guidance for the current fiscal year published on 21 March 2025, due to current focus and cost-saving measures.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer (“CFO”), effective immediately. Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. He brings deep financial expertise in facilitating successful product launches, establishing scalable operations in global markets and enabling corporate transactions. He joins Immatics from Anthos Therapeutics, a Novartis company, where he served as CFO. He will succeed Immatics’ current CFO, Arnd Christ.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the initiation of Cohort 9 in its ongoing Phase I/IIa dose escalation trial of HDP-101, the Company’s lead ATAC candidate for the treatment of relapsed or refractory multiple myeloma.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today resolved with the approval of the Supervisory Board to implement extensive cost-saving measures and consequently, to focus all development activities exclusively on lead ADC candidate HDP-101 to extend the Company’s cash reach. This is due to the delay of an expected milestone payment of USD 70 million from the royalty financing agreement with HealthCare Royalty (HCRx), as the payment condition has not yet been met.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the peer-reviewed publication in eBioMedicine of results from the completed Phase 1b/2a trial of active immunotherapy ACI-35.030’s (JNJ-2056) partnered with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company. ACI-35.030 generated a rapid, robust and durable polyclonal response against pathological forms of Tau including phosphorylated Tau (pTau) and brain-derived Tau (enriched paired helical filament, ePHF). There were no clinically relevant safety or tolerability observations for either ACI-35.030 or JACI-35.054.
Heidelberg Pharma AG, a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from its Phase I/IIa clinical study with lead Amanitin-based ADC candidate, HDP-101, will be presented at the 22nd International Myeloma Society (IMS) Annual Meeting, being held in Toronto, Canada, on 17 to 20 September 2025.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces that following a strategic review by executive management, the Company is sharpening its focused investment on its most important assets. These include its three clinical-stage active immunotherapy programs, two of which are in ongoing pharma collaborations, and its most promising small molecule programs targeting NLRP3 and Tau. As a result, the Company will reduce its workforce by around 30% and extend its cash for operations to the end of Q3 2027.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its licensing partner Telix Pharmaceuticals Limited, headquartered in Melbourne, Australia, (ASX: TLX, NASDAQ: TLX; Telix) was informed by the US Food and Drug Administration (FDA) that deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package have been identified.
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending European approval of Winlevi® (clascoterone 1% cream) for the treatment of facial acne vulgaris in both adults and adolescents aged 12 to <18 years. The decision follows a successful re-examination of the initial negative CHMP opinion issued in April.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today provided a business update and reported financial results for the quarter ended June 30, 2025.
Cosmo Pharmaceuticals N.V., a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of its multi-year manufacturing and supply agreement with Takeda (TSE:4502/NYSE:TAK), to produce Mesalazine MMX 1200 mg (marketed as Lialda® in the USA and as Mezavant in Europe) oral, once-daily treatment for ulcerative colitis, reinforcing its position as a trusted partner for global production of key medicines.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended June 30, 2025, and provided a corporate update.
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today reported strong half-year results for 2025, underscoring the Company’s strategic execution, commercial momentum, and capital discipline across its key growth platforms.
Cosmo Pharmaceuticals N.V., a global leader in AI-driven healthcare and specialty pharmaceuticals, is pleased to announce the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its first entry into Southeast Asia through the partnership with Hyphens Pharma International Limited (“Hyphens Pharma”). Winlevi® is a topical treatment for acne vulgaris in patients aged twelve years and older, marking a significant milestone in the commitment of both companies to providing innovative, patient-focused dermatology solutions.
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced a major leap forward in its sustainability journey, underscoring its ambition to lead the next decade of healthcare innovation with purpose, transparency, and impact.
Heidelberg Pharma AG published today its financial report on the first six months of 2025 (1 December 2024 – 31 May 2025) and reported about the course of business.
JIANGSU, China and HEIDELBERG, Germany, and CAMBRIDGE, MA, USA, July 8th, 2025 – Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announce today that the China National Medical Products Administration (NMPA) has approved Heng Qin® (Perfluorohexyloctane Eye Drops) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months.
Cosmo N.V., a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced its vision through 2030, along with a bold strategic plan, during its Investor Day event in Zurich.
Cosmo today announced the signing of an agreement to sell “Digital Trust” to its existing customer Tinexta InfoCert, Europe’s largest Certification Authority and a subsidiary of Tinexta S.p.A., a publicly listed company in Italy. The transaction is expected to close by the end of June 2025 and will generate €8.3 million in revenue for Cosmo.
Cosmo Pharmaceuticals N.V. today announced that in July 2025, it will initiate their first usability study of a medical device software application connecting the Medtronic GI Genius™ intelligent endoscopy module, an AI-powered platform for gastrointestinal endoscopy, with Apple Vision Pro. The study, to be conducted at Rush University Medical Center in Chicago under the leadership of Irving Waxman, MD, James R. Lowenstine Professor and Chief, Division of Digestive Diseases & Nutrition, will evaluate the real-time use of this innovative technology during live colonoscopy procedures.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the presentation of expanded data from the ongoing Phase 1b clinical trial evaluating IMA203 PRAME cell therapy in heavily pretreated patients with metastatic melanoma. The longer follow-up of patients demonstrates a consistent and favorable tolerability profile as well as durable responses with a confirmed ORR of 56%. In addition, the Company provided details from a Trial in Progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a checkpoint inhibitor.
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting. A total of 9,135,061 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 52.07% of the total outstanding ordinary shares in the share capital of Cosmo as of the record date.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the first patient has been dosed in a Phase I clinical study evaluating HDP-102 for the treatment of non-Hodgkin lymphoma (NHL).
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the company’s shareholders approved the management proposals with a large majority (between 98.03% and 99.99%) at today’s ordinary virtual Annual General Meeting.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting new clinical data on its lead Amanitin-based ADC candidate, HDP-101 at the 30th European Hematology Association (EHA) Congress, taking place in Milan, Italy, from 12 – 15 June 2025.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended March 31, 2025.
Cosmo is attending this year’s Digestive Disease Week® (DDW), held in San Diego, California from May 3-6, where its leadership team is advancing a focused agenda of strategic meetings with key opinion leaders (KOLs), innovators, and potential partners in AI and gastrointestinal (GI) drug development.
Cosmo is excited to announce that Endovision Limited, a leading innovator in endoscopic imaging solutions, has received EU MDR certification for Cerebro, a Real-Time AI-powered guide for complete Esophagogastroduodenoscopy (EGD) procedures. As one of the first Computer-Assisted Quality (CAQ) tools for endoscopy, Cerebro marks a significant step forward in transforming procedures by elevating inspection quality, standardizing protocols, and ultimately enhancing patient outcomes. Cerebro software is intended to be distributed later this year via the AI Access™ platform integrated into the Medtronic GI Genius™ intelligent endoscopy system, which is manufactured by Cosmo.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended March 31, 2025, and provided a corporate update.
Cosmo Pharmaceuticals N.V. (“Cosmo” or the “Company”) today announced the convening of its Annual General Meeting 2025 to be held on Friday 30 May 2025, at 12:00 CEST, at Strawinskyhuis, Prinses Amaliaplein 3, 1077 XS Amsterdam, the Netherlands. The agenda includes, inter alia, the following discussion and voting items:
Following the recent CHMP opinion regarding the marketing authorization application for Winlevi® (clascoterone cream 1%) in Europe, Cosmo Pharmaceuticals N.V. confirms that its financial guidance for 2025 remains unchanged.
Cosmo Pharmaceuticals N.V. announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion on the marketing authorization application (MAA) for Winlevi® (clascoterone cream 1%) for the treatment of acne vulgaris.
Heidelberg Pharma AG today reported on the first three months of fiscal year 2025 (1 December 2024 – 28 February 2025) and the Group’s financial figures.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced additional interim safety and positive immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate, for the treatment of patients with early Parkinson’s disease (PD).
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2024.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting its latest ADC research results and advancement for its Exatecan-based ADC technology platform at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois, USA, from 25 to 30 April.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) taking place in Vienna, Austria, on April 1 – 5, 2025. AC Immune will host an industry symposium highlighting advances in the clinical development of active immunotherapies featuring key opinion leaders, industry experts and AC Immune leadership.
Heidelberg Pharma AG today published its financial results and Annual Report for fiscal year 2024 (1 December 2023 – 30 November 2024) and its outlook for 2025.
Cosmo Pharmaceuticals N.V. (“Cosmo”) has published today its Annual Report for the fiscal year ending December 31, 2024. As already outlined in the unaudited 2024 Full-Year results on March 6, 2025, the reporting year was characterized by strong financial performance, exceptional revenue growth, significant strategic advancements, and a clear roadmap for future sustained corporate developments.
Heidelberg Pharma AG, a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed an amendment to the royalty financing agreement entered into in March 2024.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, 2024, and provided a corporate update.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today reported its unaudited results for the fiscal year ending December 31, 2024. The consolidated and audited 2024 Full-Year results along with the 2024 Annual Report and ESG Report will be published on March 21, 2025.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the company’s management will participate in the following investor conferences in March:
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo’s commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team.
Cosmo Pharmaceuticals N.V. (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a global research-led pharmaceutical company, today announced that Glenmark had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi® in the United Kingdom. Winlevi® is a topical treatment for acne vulgaris in patients aged 12 years and older, marking a significant milestone in the commitment of both companies to providing innovative, patient-focused dermatology solutions.
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced today that it will publish its unaudited Full-Year 2024 results on Thursday, 6 March 2025 at 7:00 am CET.
Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma.
Cosmo Pharmaceuticals N.V. (“Cosmo”) reports strong preliminary unaudited 2024 revenue and year end cash, reflecting exceptional revenue growth and a solid cash position. Cosmo will publish 2024 audited consolidated financial statements and Annual Report 2024 on March 20, 2025.
Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce the appointment of Dominika Spilarova as its Chief Strategy Officer, effective January 10, 2025. This newly created role within Cosmo’s leadership team highlights the company’s focus on strategy-led growth and innovation. She will be reporting to the CEO.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim safety and tolerability data from the ABATE Phase 1b/2 trial of ACI-24.060 in individuals living with Down syndrome (DS). Targeting toxic forms of amyloid beta (Abeta), ACI-24.060 is an active immunotherapy covering Abeta 1-15 (excluding Abeta T-cell epitopes). The interim analysis was based on data from the first two cohorts of individuals with DS receiving low-dose and mid-dose ACI-24.060. DS subjects in the interim analysis have been treated for up to one year, with no serious adverse events related to the study drug and no case of amyloid-related imaging abnormalities (ARIA) observed in this study population.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended September 30, 2024. The Company also reported the first clinical data update from the ongoing Phase 1 dose escalation trial evaluating its next-generation, half-life extended TCR Bispecific molecule, TCER® IMA402 targeting PRAME.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced positive interim safety and immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate, for the treatment of patients with early Parkinson’s disease (PD).
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 London Healthcare Conference, taking place in-person in London on November 19-21, 2024.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced an expanded clinical dataset from the ongoing Phase 1b dose expansion clinical trial for ACTengine® IMA203 in addition to updated Phase 1 dose escalation clinical data on its next-generation ACTengine® IMA203CD8 TCR-T cell therapy. For the first time, the Company also reported preclinical data on other next-generation T cell candidates and combination strategies as part of its strategy to further exploit opportunities in additional solid tumor types within its PRAME franchise.
Heidelberg Pharma AG, a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting, taking place from 7-10 December 2024 in San Diego, California, USA.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended September 30, 2024, and provided a corporate update.
Heidelberg Pharma AG, a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), announces it will present its ADC candidates and ADC technology platforms at leading scientific and financial conferences throughout November.
Cosmo shareholders today approved the proposal by the Board of Directors to appoint Deloitte Accountants B.V. as new independent auditor of the Company for the financial year ending on 31 December 2024.
Cosmo Pharmaceuticals N.V. (“Cosmo”) is delighted to announce the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016.
Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $150 million. The offering is expected to close on October 15, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,437,500 additional shares at the public offering price, less the underwriting discount.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced updated Phase 1b clinical data on ACTengine® IMA203 TCR-T targeting PRAME in melanoma patients and provided an update on SUPRAME, the upcoming Phase 3 trial to evaluate IMA203 in metastatic melanoma patients.
Heidelberg Pharma AG reported today on its operational progress as well as on the Group’s financial figures for the first nine months of fiscal year 2024 (1 December 2023 – 31 August 2024).
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, and Laboratoires Théa (Théa), the leading independent eye care group in Europe, announce European Commission approval of Vevizye® (ciclosporin 0.1% eye drops solution) in Europe and the closing of a partnership under which Théa has acquired the rights to commercialise the product in Europe and selected countries in the Middle East and North Africa (MENA).
Heidelberg Pharma AG, a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data from its lead Amanitin-based ADC candidate, HDP-101, were presented at the International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil on 27 September 2024.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it has adjusted its guidance for the current fiscal year published on 18 June 2024 downwards on the cost side.
Cosmo Pharmaceuticals N.V. (“Cosmo”) is excited to announce the appointment of Ms. Egle Gedrimaite, as the new Head of Global Business Development, effective October 1, 2024. Egle Gedrimaite will report to Giovanni Di Napoli, CEO of Cosmo. With extensive experience in expanding global business operations and driving strategic market growth, Egle is a valuable addition to Cosmo’s management team, as the Company continues its ambitious expansion plans.
Heidelberg Pharma AG, a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from its Phase I/IIa clinical study with lead Amanitin-based ADC candidate, HDP-101, will be presented at the 21st International Myeloma Society (IMS) Annual Meeting, being held in Rio De Janeiro, Brazil on 25 to 28 September 2024.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today presented the proof-of-concept clinical data for the first candidate of its next-generation, half-life extended TCR Bispecifics platform, TCER® IMA401 (MAGEA4/8), during an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024.
Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (“Cosmo”), the developer and manufacturer of the GI Genius™ intelligent endoscopy system, is pleased to announce the publication of a study in “The Lancet”. This study, titled “Polyp detection with colonoscopy assisted by the GI Genius™ artificial intelligence endoscopy module compared with standard colonoscopy in routine colonoscopy practice (COLO-DETECT): a multicentre, open-label, parallel-arm, randomised controlled trial”, represents a significant advancement in colorectal cancer screening and detection.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that its partner Life Molecular Imaging (LMI) has received Fast Track Designation for the Tau positron emission tomography (PET) diagnostic, [18F]PI-2620, from the U.S. Food and Drug Administration (FDA) in three neurodegenerative conditions.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended June 30, 2024.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended June 30, 2024, and provided a corporate update.
Immatics N.V. (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the appointment of Alise Reicin, M.D., to its Board of Directors. Alise Reicin is an experienced and expert pharmaceutical industry executive and leader who has led the development of multiple important new therapies, including Keytruda®. Dr. Reicin currently serves as the President and CEO of Tectonic Therapeutic and is also a member of the Board of Directors of Sana Biotechnology. She joins Immatics’ Board of Directors as the Company advances its pipeline of novel TCR-based cell therapy and bispecific product candidates into the next phase of development.
Cosmo Intelligent Medical Devices, a division of Cosmo Pharmaceuticals N.V. (“Cosmo”) focused on pioneering medical devices powered by Artificial Intelligence, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the next generation GI Genius™ hardware, the latest development of the GI Genius™ intelligent endoscopy system, which Medtronic exclusively distributes globally. This milestone reaffirms the GI Genius™ platform’s leadership in AI-enhanced endoscopy and marks a significant advancement in the realm of medical technology.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today unveiled a novel class of neurodegenerative disease-fighting drug-candidates called morADC (Morphomer® Antibody Drug Conjugate) in an oral presentation at the annual Alzheimer’s Association International Conference (AAIC 2024), taking place from July 28 – August 1, 2024, in Philadelphia, PA.
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announces that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorisation in the European Union for Vevizye®, intended for the treatment of moderate to severe dry eye disease in adult patients, which has not improved despite treatment with tear substitutes.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its active-immunotherapy candidate, ACI-35.030 (now called JNJ-2056), targeting the pathologic form of the Tau protein, phosphorylated Tau (pTau), has received Fast Track designation from the U.S. Food and Drug Administration (FDA). The recently initiated Phase 2b clinical trial ReTain is currently recruiting participants with preclinical Alzheimer’s disease, where individuals have yet to show clinical symptoms.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced three oral presentations highlighting its precision medicine pipeline at the annual Alzheimer’s Association International Conference (AAIC 2024), taking place in Philadelphia, PA, on July 28 – August 1, 2024.
Cosmo shareholders today approved all resolutions proposed by the Board of Directors at an Extraordinary General Meeting of the Company. A total of 7,173,931 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders constituting 40.89% of the total outstanding ordinary shares in the share capital of Cosmo as of the record date.
Heidelberg Pharma AG announced that the company’s shareholders approved the following proposed resolutions of the management with a large majority (between 98,35% and 99,99%) at yesterday’s ordinary virtual Annual General Meeting:
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it has adjusted its guidance for the current fiscal year published on 25 March 2024.
Cosmo Pharmaceuticals N.V. (“Cosmo”) reported that its partner and exclusive licensee of Lumeblue® (Methylene Blue MMX®) for China, China Medical System Holdings Limited (“CMS”) (SEHK: 867), has received the approval for the innovative product in the territory by the National Medical Products Administration of China (NMPA) on 11 June. Today, on 18 June, CMS also obtained the corresponding Drug Registration Certificate. Cosmo will be the exclusive supplier for the product.
Cosmo Pharmaceuticals N.V. (“Cosmo”) with its Cosmo Intelligent Medical Devices division (“Cosmo IMD”) is consolidating its strategy to accelerate the adoption of responsible and regulated AI in healthcare, obtaining pragmatic results in its mission to address unmet clinical needs and improve patient outcomes.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 Global Healthcare Conference, taking place in-person in New York on June 5-6, 2024.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that its shareholders approved all agenda items at today’s annual general meeting of shareholders.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating and presenting on its proprietary ADC technology platforms at the following scientific conferences in May and June in 2024.
Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended March 31, 2024.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the quarter ended March 31, 2024, and provided a corporate update.
Takeda and AC Immune SA today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024.
Heidelberg Pharma AG today reported on the first three months of fiscal year 2024 (1 December 2023 – 29 February 2024) and the Group’s financial figures.
Cosmo Pharmaceuticals N.V. (“Cosmo”) announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system developed by Cosmo IMD, along with a new strategic collaboration designed to enhance patient care.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).
Heidelberg Pharma AG today published its financial results and Annual Report for fiscal year 2023 (1 December 2022 – 30 November 2023) and its outlook for 2024.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the formal closing of the royalty purchase agreement with HealthCare Royalty (HCRx) for Zircaix®, signed earlier this month.
Cosmo Pharmaceuticals N.V. (“Cosmo”) reported today that its partner Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (“Sun Pharma”) has announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi® (clascoterone cream 1%). Winlevi® is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it will be advancing into an expanded Cohort 6 dose escalation following submission of a protocol amendment to the US Food and Drug Administration (FDA) for its Phase I/IIa study with lead ATAC candidate HDP-101 for the treatment of multiple myeloma.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the year ended December 31, 2023, and provided a corporate update.
Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs) will be presenting first efficacy data on its Phase I clinical trial with ATAC candidate HDP-101 as well as preclinical data on other drug candidates from its proprietary ADC technology platform at the American Association for Cancer Research (AACR) Annual Meeting, being held in San Diego, California on the 5 – 10 April 2024.
Heidelberg Pharma AG, a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement. Formal closing conditions that are expected to be fulfilled in a timely manner must still be met. Heidelberg Pharma is eligible to receive up to USD 115 million from the sale of its future royalties from worldwide sales of Zircaix™ (TLX250-CDx), a microdose radiopharmaceutical Positron Emission Tomography (PET) imaging agent for the diagnosis and follow up of clear cell renal cancer.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024), taking place in Lisbon, Portugal March 5-9, 2024. In addition, Andrea Pfeifer, Ph.D., CEO of AC Immune SA will lead an industry symposium exploring the latest clinical advances in the diagnosis and treatment of alpha-synuclein pathologies.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company will regain all global rights to the anti-amyloid beta antibody crenezumab and the anti-Tau antibody semorinemab following termination of the collaboration agreements with Genentech, a member of the Roche Group, and Roche. Both antibodies have been evaluated in clinical studies for Alzheimer’s disease (AD). AC Immune will also regain rights to existing GMP drug-product for clinical testing as well as associated data generated under each of the agreements. AC Immune will carefully review and evaluate available data sets, including the final open label extension results from the Lauriet trial when they become available and are received in full by AC Immune, before decisions are made on potential further development and other opportunities.
Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $175 million. The offering is expected to close on January 22, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,388,750 additional shares at the public offering price, less the underwriting discount.
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today provided an update on positive progress in its active immunotherapy programs, with three Phase 2 trials progressing to key clinical milestones in 2024.
